Ó³»­´«Ã½

Skip to main content
Home

Top menu

  • Careers
Search
  • Ó³»­´«Ã½
      1. This is Ó³»­´«Ã½ Learn about our mission, our values, our history, and partner institutions.
      2. People Meet our members, staff scientists, fellows, leadership, and other Ó³»­´«Ã½ies.
      3. Join Ó³»­´«Ã½ Find out how to join the Ó³»­´«Ã½ as an employee or associate member.
      4. Contact us Find our contact information, directions to our buildings, and directory.
  • Research
      1. Disease areas Ó³»­´«Ã½ brings people together to advance the understanding and treatment of disease.
        1. Items Wpapp col
          • Cancer
          • Cardiovascular disease
          • Brain Health
          • Diabetes
          • Infectious disease and microbiome
          • Kidney disease
          • Obesity
          • Rare disease
      2. Research areas Through programs spanning genetics, biology, artificial intelligence (AI), and therapeutic development, Ó³»­´«Ã½ researchers are making discoveries that drive biomedical science forward.
        1. Items Wpapp col
          • AI and machine learning
          • Chemical biology and therapeutics science
          • Drug discovery
          • Genome regulation, cellular circuitry, and epigenomics
          • Immunology
          • Medical and population genetics
          • Metabolism
      3. Technology areas Our researchers use their expertise in creating, adapting, and applying a variety of technologies to enable science here and beyond.
        1. Items Wpapp col
          • Data sciences
          • Genetic perturbation
          • Genomics
          • Imaging
          • Metabolomics
          • Proteomics
          • Spatial technologies
      4. Science
        1. Patient-partnered research Patients partner with our scientists to accelerate the pace of discovery and find better treatments.
        2. Partnering and licensing We work closely with pharmaceutical, biotech, and technology partners to accelerate the translation of our discoveries.
        3. Publications A catalog of scientific papers published by our members and staff scientists.
        4. Resources, services, and tools Key scientific datasets and computational tools developed by our scientists and their collaborators.
        5. Collaborations and consortia We join with institutions and scientists the world over to address foundational challenges in science and health.
  • Centers
      1. Carlos Slim Center for Health Research The Slim Center aims to bring the benefits of genomics-driven medicine to Latin America, gleaning new insights into diseases with relevance to the region.
      2. Gerstner Center for Cancer Diagnostics The Gerstner Center is developing next-generation diagnostic technology for cancer detection and tracking disease progression.
      3. Klarman Cell Observatory The Klarman Cell Observatory is systematically defining mammalian cellular circuits, how they work together to create tissues and organs, and are perturbed to cause disease.
      4. Merkin Institute for Transformative Technologies in Healthcare The Merkin Institute is supporting early-stage ideas aimed at advancing powerful technological approaches for improving how we understand and treat disease.
      5. Novo Nordisk Foundation Center for Genomic Mechanisms of Disease This center is developing new paradigms and technologies to scale the discovery of biological mechanisms of common, complex diseases, by facilitating close collaborations between the Ó³»­´«Ã½ and the Danish research community.
      6. Eric and Wendy Schmidt Center The EWSC is catalyzing a new field of interdisciplinary research at the intersection of data science and life science, aimed at improving human health.
      7. Stanley Center for Psychiatric Research The Stanley Center aims to reduce the burden of serious mental illness by contributing new insights into pathogenesis, identifying biomarkers, and paving the way toward new treatments.
  • Education and outreach
      1. Art and science connection Explore the connection between art and science and how we bring together artists and Ó³»­´«Ã½ scientists through our artist-in-residence program, gallery exhibitions, and ongoing public conversations.
      2. Ó³»­´«Ã½ Discovery Center Visit our free public educational space that showcases how researchers at the Ó³»­´«Ã½ and their colleagues around the world seek to understand and treat human disease.
      3. Learning resources Access free classroom materials and more for STEM educators, parents, students, tutors, and others.
      4. Public programs Discover remarkable stories of scientific progress, and explore the intersections of science, medicine, and society.
      5. Student opportunities Learn about Ó³»­´«Ã½'s mentored research offerings for high school students, college students, and recent college graduates.
      6. Visit Ó³»­´«Ã½ Come see what Ó³»­´«Ã½ is all about.
  • News
      1. News and insights Learn about breakthroughs from Ó³»­´«Ã½ scientists.
        1. Column
      2. Press room Contact our media relations team.
        1. Column
      3. Sign up for our newsletter Receive regular updates on Ó³»­´«Ã½ news, research and community.
  • Careers
  • Search
Effects of parental autoimmune diseases on type 1 diabetes in offspring can be partially explained by HLA and non-HLA polymorphisms.
Wang F, Liu A, Yang Z, et al. Effects of parental autoimmune diseases on type 1 diabetes in offspring can be partially explained by HLA and non-HLA polymorphisms. Cell genomics. 2025:100854. doi:10.1016/j.xgen.2025.100854
Read more
Genotype-Phenotype Low-Density Lipoprotein Cholesterol Discordance and Coronary Artery Disease Risk.
Shankar A, Truong B, Koyama S, et al. Genotype-Phenotype Low-Density Lipoprotein Cholesterol Discordance and Coronary Artery Disease Risk. JACC. Advances. 2025;4(5):101677. doi:10.1016/j.jacadv.2025.101677
Read more
Effects of parental autoimmune diseases on type 1 diabetes in offspring can be partially explained by HLA and non-HLA polymorphisms.
Wang F, Liu A, Yang Z, et al. Effects of parental autoimmune diseases on type 1 diabetes in offspring can be partially explained by HLA and non-HLA polymorphisms. Cell genomics. 2025:100854. doi:10.1016/j.xgen.2025.100854
Read more
Type 2 diabetes and late-onset Alzheimer's disease and related dementia: A longitudinal cohort study integrating polygenic risk score.
Jeong S, Lin L, Leone AP, Hsu YH. Type 2 diabetes and late-onset Alzheimer’s disease and related dementia: A longitudinal cohort study integrating polygenic risk score. Journal of Alzheimer’s disease : JAD. 2025:13872877251326107. doi:10.1177/13872877251326107
Read more
Identification of Hub Genes Involved in Early-onset Schizophrenia: From Genetic Susceptibility to Predicted Regulated Gene Expression.
Jen Y, Yu SL, Hsiao PC, et al. Identification of Hub Genes Involved in Early-onset Schizophrenia: From Genetic Susceptibility to Predicted Regulated Gene Expression. Research square. 2025. doi:10.21203/rs.3.rs-5833160/v1
Read more
Clinical utility and implementation of polygenic risk scores for predicting cardiovascular disease.
Schunkert H, Di Angelantonio E, Inouye M, et al. Clinical utility and implementation of polygenic risk scores for predicting cardiovascular disease. European heart journal. 2025. doi:10.1093/eurheartj/ehae649
Read more
Genetic vulnerability and adverse mental health outcomes following mild traumatic brain injury: a meta-analysis of CENTER-TBI and TRACK-TBI cohorts.
Kals M, Wilson L, Levey DF, et al. Genetic vulnerability and adverse mental health outcomes following mild traumatic brain injury: a meta-analysis of CENTER-TBI and TRACK-TBI cohorts. EClinicalMedicine. 2024;78:102956. doi:10.1016/j.eclinm.2024.102956
Read more
The PRIMED Consortium: Reducing disparities in polygenic risk assessment.
Kullo IJ, Conomos MP, Nelson SC, et al. The PRIMED Consortium: Reducing disparities in polygenic risk assessment. American journal of human genetics. 2024. doi:10.1016/j.ajhg.2024.10.010
Read more
The PRIMED Consortium: Reducing disparities in polygenic risk assessment.
Kullo IJ, Conomos MP, Nelson SC, et al. The PRIMED Consortium: Reducing disparities in polygenic risk assessment. American journal of human genetics. 2024. doi:10.1016/j.ajhg.2024.10.010
Read more
Polygenic risk, aspirin and primary prevention of coronary artery disease.
Yu C, Natarajan P, Patel AP, et al. Polygenic risk, aspirin and primary prevention of coronary artery disease. European heart journal. Cardiovascular pharmacotherapy. 2024. doi:10.1093/ehjcvp/pvae085
Read more

Pagination

  • Current page 1
  • Page 2
  • Page 3
  • Page 4
  • Next page ›â¶Äº

Address

Merkin Building
415 Main St.
Cambridge, MA 02142

Follow Us

Home

Sign up for our newsletter

Did you know?

In March of 2020, Ó³»­´«Ã½ converted a clinical genetics processing lab into a large-scale COVID-19 testing facility in less than two weeks.

We've screened more than 1,275 cancer cell lines as part of the Cancer Dependency Map (DepMap).

Ó³»­´«Ã½ Genomics Platform sequences a whole human genome every four minutes.

More than 11,000 individuals living with cancer in the United States and Canada have partnered with Count Me In to share their experiences and help accelerate cancer research.

The Drug Repurposing Hub is one of the most comprehensive and up-to-date biologically annotated collections of FDA-approved compounds in the world. Researchers anywhere can explore more than 6,000 drugs in the hub and search for possible new uses for them to jump-start new drug discovery.

In 2021, our sustainability efforts sent more than 80 percent of waste from the Genomics Platform to either a recycling facility or to an incineration plant that generates electricity.

Through Ó³»­´«Ã½'s Scientists in the Classroom program, Ó³»­´«Ã½ researchers visit every 8th grade classroom in Cambridge each year to talk about genetics and evolution.

Every summer, 18 high school students spend six weeks at Ó³»­´«Ã½ working side-by-side with mentors on cutting-edge research.

In November 2022, Ó³»­´«Ã½â€™s Genomics Platform sequenced its 500,000th whole human genome, a mere four years after sequencing its 100,000th.

By the end of 2022, Ó³»­´«Ã½â€™s COVID-19 testing lab had processed more than 37 million tests.

Working with Addgene, Ó³»­´«Ã½ has shared CRISPR genome-editing reagents with researchers at more than 3,200 institutions in 76 countries.

The NeuroGAP-Psychosis project, a collaboration between the Stanley Center for Psychiatric Research and Harvard T.H. Chan School of Public Health to study the genetics of severe mental illness, has recruited more than 42,000 participants in Ethiopia, Kenya, Uganda, and South Africa.

Footer menu

  • Report a concern
  • Contact Us
  • Privacy Policy

© Ó³»­´«Ã½ 2025